Development Programs
Novel small molecules for mental health indications
Development Programs
Discovery
Preclinical
Phase 1
Phase 2
EVM201 Series
Anxiety Disorders
EVM301 Series
Undisclosed
Anxiety Disorders
Anxiety Continues to be a Large Unmet Need with Limited Innovative Treatments
- Anxiety disorders are the second most common central nervous system disorders.
- Persons living with anxiety disorders experience the ailments and debilitating effects of chronic conditions, affecting their quality of life.
Percent of Adults Ages 18-64 in the General Population Who Meet Diagnostic Criteria for Anxiety Disorders in the Past Year and in Their Lifetime
Limitations of Current Anxiety Pharmacologic Treatments
Anxiolytics
Key Limitations
- Limited efficacy with significant number of patients with residual untreated symptoms
- Safety and tolerability issues, including GI upset, sexual dysfunction, serotonin toxicity, and more
- Risk of abuse and dependence, particularly with the chronic use of benzodiazepines
1st Generation Psilocybin
Key Limitations
- Effectiveness not confirmed (currently under investigation)
- Challenges with patentability
- Anecdotal evidence in the absence of rigorous investigations
- Safety and tolerability issues
Schmitz A. Benzodiazepine use, misuse, and abuse: A review. Mental Health Clin (2016) 6(3): 120–126. Passie et al. The Pharmacology of Psilocybin. Addiction Biology (2002) 7, 357–364. Kessler, Petukhova et al., 2012. Copyright © John Wiley & Sons, Inc. All Rights Reserved.
Potential Expansion Indications
Novel Treatment Paradigm
- Optimized treatment regimen for quick, profound and lasting behavioral changes.
- Monotherapy and/or adjunctive therapy as Single Administration (SA) with Individualized Repeat Dosing (IRD) for a Precision Medicine approach to tailor individual patient needs.
- Drug administration inside a clinical setting (under minimal supervision of a health care professional) or outside a clinical setting (provided it is deemed safe to do so).
Discovering Next-generation Treatments for Mental Illness
Our mission is to pioneer a paradigm shift and generate new solutions with the potential to have profound effects on patients and their families, and to deliver life-changing medicines for diseases affecting the brain, such as anxiety, depression, and addiction.
